BioVie, an early stage biotech developing therapies for cirrhosis, announced terms for its IPO on Tuesday.
The Los Angeles, CA-based company plans to offer 1.3 million shares and raise $15 million based on an offer price of $11.88, the as-converted last close of its shares listed on the OTC (BIVI). At this price, BioVie would command a fully diluted market value of $64 million.
BioVie was founded in 2013 and plans to list on the Nasdaq under the symbol BIVI. ThinkEquity is the sole bookrunner on the deal.
Microcap cirrhosis biotech BioVie sets terms for $15 million IPO
July 9, 2019

